About AusperBio
AusperBio is a company based in San Mateo (United States) founded in 2019 by Guofeng Cheng and Chris Yang. AusperBio has raised $223 million across 4 funding rounds from investors including Qiming Venture Partners, Hankang Capital and Sherpa Capital. AusperBio offers products and services including Med-Oligo ASO Platform. AusperBio operates in a competitive market with competitors including Eiger BioPharmaceuticals, Aligos Therapeutics, Ascentage Pharma, Bluejay Therapeutics and Presidio Pharmaceuticals, among others.
- Headquarter San Mateo, United States
- Founders Guofeng Cheng, Chris Yang
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$223 M (USD)
in 4 rounds
-
Latest Funding Round
$63 M (USD), Series B
Sep 21, 2025
-
Investors
Qiming Venture Partners
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AusperBio
AusperBio offers a comprehensive portfolio of products and services, including Med-Oligo ASO Platform.
Platform for targeted delivery of ASO therapeutics to treat various diseases.
Funding Insights of AusperBio
AusperBio has successfully raised a total of $223M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $63 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AusperBio
AusperBio has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiming Venture Partners, Hankang Capital and Sherpa Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Private equity investments are directed toward opportunities in Spain.
|
Locked | Locked | Locked | |
|
Private equity and private debt firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for AusperBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AusperBio
Investment portfolio details for AusperBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AusperBio
Detailed financials for AusperBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ausperbio Comparisons
Peer comparison for AusperBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AusperBio
AusperBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Eiger BioPharmaceuticals, Aligos Therapeutics, Ascentage Pharma, Bluejay Therapeutics and Presidio Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| Locked | Locked | Locked |
Developer of therapies to treat hepatologic diseases and viral infections
|
|
| Locked | Locked | Locked |
Small molecule drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for infectious diseases treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule antiviral therapeutics for hepatitis C are developed.
|
Detailed competitors of AusperBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ausperbio
Complete news archive for AusperBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AusperBio
AusperBio was founded in 2019 and raised its 1st funding round 5 years after it was founded.
AusperBio is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Guofeng Cheng is the current CEO of AusperBio. They have also founded this company.
AusperBio is a funded company, having raised a total of $223M across 4 funding rounds to date.
AusperBio was founded in 2019 in San Mateo, United States, within the biotechnology sector. Focus is placed on developing treatments for chronic hepatitis B and other major infectious diseases. A pipeline of oligonucleotide therapeutics is maintained, featuring AHB-137, which utilizes conjugation technology for targeted delivery. This approach integrates DNA replication inhibitors, HBsAg inhibitors, and immunomodulators to address disease mechanisms. Operations emphasize research and therapeutic innovation in infectious disease management.
AusperBio's top competitors include Eiger BioPharmaceuticals, Finch Therapeutics and Aligos Therapeutics.
AusperBio offers Med-Oligo ASO Platform.
AusperBio has 9 investors. Key investors include Qiming Venture Partners, Hankang Capital, Sherpa Capital, CDH, and BioVenture.